NCCN Updates Cancer- and Treatment-Related Anemia Guidelines
FORT WASHINGTON, Pa., December 20, 2007 — The National Comprehensive Cancer Network (NCCN) announces important updates to the NCCN Cancer- and Treatment-Related Anemia Guidelines relating to the use of erythropoietin-stimulating agents (ESAs), such as epoetin alfa and darbepoetin alfa.
ESAs are no longer recommended for the treatment of cancer-related anemia associated with solid tumors or hematologic malignancies other than myelodysplastic syndromes (MDS). ESA therapy is an option for patient...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news
More News: Anemia | Aranesp | Cancer | Cancer & Oncology | Epogen | Hematology | Myelodysplastic Syndrome | Procrit